{"nctId":"NCT01933919","briefTitle":"A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder","startDateStruct":{"date":"2013-08-14","type":"ACTUAL"},"conditions":["Obsessive Compulsive Disorder"],"count":38,"armGroups":[{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Fluvoxamine maleate","Drug: Placebo"]},{"label":"Fluvoxamine","type":"EXPERIMENTAL","interventionNames":["Drug: Fluvoxamine maleate"]}],"interventions":[{"name":"Fluvoxamine maleate","otherNames":["SME3110","Luvox","Depromel"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subject has at least 16 points on Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale 10-item total score and at least 5 points in Obsession sub-total score and in Compulsion sub-total score respectively at the Screening period and Baseline.\n2. Subject showed less than 25% reduction in Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale 10-item total score at Baseline compared to the score at the Screening period (Total score at Baseline ≥ Total score at Screening х 0.75).\n3. Subject has obsessive compulsive disorder symptoms at least for 2 months at informed consent.\n4. Body weight: ≥ standard weight - 2 standard deviation based on the standard weight for each age in the School Health Statistical Survey 2001.\n5. Subjects with parent or legal guardian who have received explanation about the purpose, procedure and meaning of the study sufficiently and is willing to give written informed consent for the subject. (if possible, written informed assent will be obtained from the subject).\n\nExclusion Criteria:\n\n1. Subject has only trichotillomania (Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 312.39) or nail-biting as his/her compulsive symptoms.\n2. Subject has Tourette's disorder (Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 307.23). However, the simple motor tic is not excluded.\n3. Subject is diagnosed with the following psychiatric disorders.\n\n   * Schizophrenia (Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 295.xx) and other psychotic disorders (Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 295.40 \\[schizophreniform disorder\\], 295.70 \\[schizoaffective disorder\\], 297.1 \\[delusional disorder\\], 298.8 \\[brief psychotic disorder\\], 297.3 \\[shared psychotic disorder\\], 293.xx \\[psychotic disorder due to… {indicate the general medical condition}\\], substance induced psychotic disorder, 298.9 \\[psychotic disorder not otherwise specified\\]).\n   * Depressive disorders Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 296.xx \\[major depressive disorder\\], 296.2x \\[single episode\\], 296.3x \\[recurrent\\], 300.4 \\[dysthymic disorder\\], 311 \\[depressive disorder not otherwise specified\\]).\n   * Bipolar disorders (Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 296.xx \\[bipolar I disorder\\], 296.0x \\[single manic episode\\], 296.40 \\[most recent episode hypomanic\\], 296.4x \\[most recent episode manic\\], 296.6x \\[most recent episode mixed\\], 296.5x \\[most recent episode depressed\\], 296.7 \\[most recent episode unspecified\\], 296.89 \\[bipolar II disorder\\], 301.13 \\[cyclothymic disorder\\], 296.80 \\[bipolar disorder not otherwise specified\\]).\n   * Mental retardation (Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 317 \\[mild mental retardation\\], 318.0 \\[moderate mental retardation\\], 318.1 \\[severe mental retardation\\], 318.2 \\[profound mental retardation\\], 319 \\[mental retardation, severity unspecified\\]).\n   * Eating disorders (Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 307.1 \\[anorexia nervosa\\], 307.51 \\[bulimia nervosa\\], 307.50 \\[eating disorder not otherwise specified\\]).\n   * Attention-deficit/hyperactivity disorder (Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 314.xx) and attention deficit/hyperactivity disorder not otherwise specified (Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 314.9).\n   * Obsessive compulsive personality disorder (Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 301.4).\n   * Other patients with clinical neurological disorder.\n4. Subject who diagnose Major Depressive Disorder by The Mini-International Neuropsychiatric Interview for Children and Adolescents (A) at the Screening period.\n5. Subject has been treated with fluvoxamine within 2 months prior to informed consent. Except for the patient whose fluvoxamine dose is not fixed and the administration period of fluvoxamine is within 6 weeks.","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline in the Japanese Children's Yale-Brown Obsessive Compulsive Scale 10-item Total Score at the End of Treatment in the First Phase","description":"The Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) is a 10-item questionnaire assessing the severity of obsessive compulsive disorder (OCD) in the past 7 days. Severity of compulsions and obsessions are rated on a scale from 0 (none) to 4 (extreme). The total score is calculated by summing the 10 individual scores and ranges from 0 to 40, where higher scores indicate more extreme symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.5","spread":"5.25"},{"groupId":"OG001","value":"-6.6","spread":"7.52"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in the JCY-BOCS 10-item Total Score at the End of Treatment in the First Phase Stratified by Age","description":"The Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) is a 10-item questionnaire assessing the severity of OCD in the past 7 days. Severity of compulsions and obsessions are rated on a scale from 0 (none) to 4 (extreme). The total score is calculated by summing the 10 individual scores and ranges from 0 to 40, where higher scores indicate more extreme symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.5","spread":"3.00"},{"groupId":"OG001","value":"-10.3","spread":"11.95"},{"groupId":"OG002","value":"-10.0","spread":"5.67"},{"groupId":"OG003","value":"-5.6","spread":"5.97"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in the JCY-BOCS 10-item Total Score at the End of Treatment in the First Phase Stratified by Gender","description":"The Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) is a 10-item questionnaire assessing the severity of OCD in the past 7 days. Severity of compulsions and obsessions are rated on a scale from 0 (none) to 4 (extreme). The total score is calculated by summing the 10 individual scores and ranges from 0 to 40, where higher scores indicate more extreme symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.9","spread":"4.68"},{"groupId":"OG001","value":"-7.0","spread":"8.38"},{"groupId":"OG002","value":"-9.3","spread":"5.68"},{"groupId":"OG003","value":"-6.0","spread":"6.51"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in the JCY-BOCS 10-item Total Score at Each Visit During the First Phase","description":"The Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) is a 10-item questionnaire assessing the severity of OCD in the past 7 days. Severity of compulsions and obsessions are rated on a scale from 0 (none) to 4 (extreme). The total score is calculated by summing the 10 individual scores and ranges from 0 to 40, where higher scores indicate more extreme symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"3.49"},{"groupId":"OG001","value":"-1.6","spread":"2.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.1","spread":"4.95"},{"groupId":"OG001","value":"-3.2","spread":"4.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.8","spread":"6.31"},{"groupId":"OG001","value":"-5.6","spread":"5.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.6","spread":"5.01"},{"groupId":"OG001","value":"-7.9","spread":"8.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.8","spread":"5.29"},{"groupId":"OG001","value":"-7.2","spread":"7.77"}]}]}]},{"type":"SECONDARY","title":"JCY-BOCS 10-item Total Score at Each Visit During the First Phase","description":"The Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) is a 10-item questionnaire assessing the severity of OCD in the past 7 days. Severity of compulsions and obsessions are rated on a scale from 0 (none) to 4 (extreme). The total score is calculated by summing the 10 individual scores and ranges from 0 to 40, where higher scores indicate more extreme symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.6","spread":"5.51"},{"groupId":"OG001","value":"27.3","spread":"5.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","spread":"6.72"},{"groupId":"OG001","value":"25.1","spread":"5.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":"7.91"},{"groupId":"OG001","value":"24.2","spread":"6.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":"7.48"},{"groupId":"OG001","value":"22.1","spread":"8.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.9","spread":"6.27"},{"groupId":"OG001","value":"19.6","spread":"10.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","spread":"6.48"},{"groupId":"OG001","value":"20.7","spread":"9.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":"6.84"},{"groupId":"OG001","value":"20.7","spread":"9.21"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Much Improved in Clinical Global Impression Improvement Assessment During the First Phase","description":"The investigator evaluated Clinical Global Impression (CGI) to rate participants' clinical symptomatology according to the following seven categories at each visit compared to the day of the first dose of study medication:\n\n1. Very much improved\n2. Much improved\n3. Minimally improved\n4. No change\n5. Minimally worse\n6. Worse\n7. Very much worse\n\nMuch improved includes CGI score categories 'very much improved' and 'much improved'.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"11.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":null},{"groupId":"OG001","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","spread":null},{"groupId":"OG001","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.9","spread":null},{"groupId":"OG001","value":"29.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.1","spread":null},{"groupId":"OG001","value":"43.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"43.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.6","spread":null},{"groupId":"OG001","value":"38.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a ≥ 25% Decrease From Baseline in JCY-BOCS (10-item) Total Score at the End of Treatment in the First Phase","description":"The Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) is a 10-item questionnaire assessing the severity of OCD in the past 7 days. Severity of compulsions and obsessions were rated on a scale from 0 (none) to 4 (extreme). The total score was calculated by summing the 10 individual scores and ranges from 0 to 40, where higher scores indicate more extreme symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.7","spread":null},{"groupId":"OG001","value":"44.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a ≥ 35% Decrease From Baseline in JCY-BOCS (10-item) Total Score at the End of Treatment in the First Phase","description":"The Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) is a 10-item questionnaire assessing the severity of OCD in the past 7 days. Severity of compulsions and obsessions were rated on a scale from 0 (none) to 4 (extreme). The total score was calculated by summing the 10 individual scores and ranges from 0 to 40, where higher scores indicate more extreme symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.4","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in the JCY-BOCS 10-item Total Score at Each Visit During the Second Phase","description":"The Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) is a 10-item questionnaire assessing the severity of OCD in the past 7 days. Severity of compulsions and obsessions are rated on a scale from 0 (none) to 4 (extreme). The total score is calculated by summing the 10 individual scores and ranges from 0 to 40, where higher scores indicate more extreme symptoms.\n\nBaseline for the 2nd phase was the first visit of the 2nd phase after completion of the tapering period in the first phase and prior to study drug administration in the 2nd phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","spread":"6.62"},{"groupId":"OG001","value":"20.4","spread":"9.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"3.93"},{"groupId":"OG001","value":"-1.1","spread":"6.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"2.87"},{"groupId":"OG001","value":"-4.3","spread":"7.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"2.95"},{"groupId":"OG001","value":"-7.1","spread":"8.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"3.87"},{"groupId":"OG001","value":"-6.2","spread":"6.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"3.97"},{"groupId":"OG001","value":"-5.6","spread":"11.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"4.48"},{"groupId":"OG001","value":"-6.6","spread":"9.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"5.48"},{"groupId":"OG001","value":"-8.1","spread":"8.61"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Much Improved in Clinical Global Impression Improvement Assessment During the Second Phase","description":"The investigator evaluated Clinical Global Impression (CGI) to rate participants' clinical symptomatology according to the following seven categories at each visit compared to the day of the first dose of study medication in the 2nd phase:\n\n1. Very much improved\n2. Much improved\n3. Minimally improved\n4. No change\n5. Minimally worse\n6. Worse\n7. Very much worse\n\nMuch improved includes CGI score categories 'very much improved' and 'much improved'.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null},{"groupId":"OG001","value":"7.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":null},{"groupId":"OG001","value":"35.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null},{"groupId":"OG001","value":"54.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null},{"groupId":"OG001","value":"46.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"60.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":null},{"groupId":"OG001","value":"53.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.7","spread":null},{"groupId":"OG001","value":"64.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"64.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null},{"groupId":"OG001","value":"53.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","spread":null},{"groupId":"OG001","value":"58.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.1","spread":null},{"groupId":"OG001","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"27.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"45.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"27.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.1","spread":null},{"groupId":"OG001","value":"36.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.1","spread":null},{"groupId":"OG001","value":"46.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events During the First Phase","description":"An adverse event (AE) was assessed as treatment-related by the investigator if there was evidence to suggest a causal relationship between the study drug and the adverse event.\n\nThe investigator used the following definitions to rate the severity of each adverse event:\n\nMild: The adverse event was transient and easily tolerated by the participant;\n\nModerate: The adverse event caused the participant discomfort and interrupted usual activities.\n\nSevere: The adverse event caused considerable interference with the participant's usual activities and may have been incapacitating or life-threatening.\n\nA serious adverse event was any event that resulted in death, was life-threatening, resulted in hospitalization or prolongation of hospitalization, congenital anomaly, persistent or significant disability/incapacity, or was an important medical event requiring medical or surgical intervention to prevent a serious outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events During the Second Phase","description":"An adverse event was assessed as treatment-related by the investigator if there was evidence to suggest a causal relationship between the study drug and the adverse event.\n\nThe investigator used the following definitions to rate the severity of each adverse event:\n\nMild: The adverse event was transient and easily tolerated by the participant;\n\nModerate: The adverse event caused the participant discomfort and interrupted usual activities.\n\nSevere: The adverse event caused considerable interference with the participant's usual activities and may have been incapacitating or life-threatening.\n\nA serious adverse event was any event that resulted in death, was life-threatening, resulted in hospitalization or prolongation of hospitalization, congenital anomaly, persistent or significant disability/incapacity, or was an important medical event requiring medical or surgical intervention to prevent a serious outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":["Nasopharyngitis","Nausea","Upper respiratory tract inflammation","Somnolence","Constipation"]}}}